- Our LinkedIn Page
- Our Twitter Feed
- Our Facebook Page
- Newsletter Subscribe to our monthly e-newsletter. Current Issue
- Our Flickr Feed
- Our YouTube Feed
Authors
- Abigail Hirsch
- Alan Eisenberg
- BIOtechNOW Editor
- Bruce Dale
- Celia Economides
- Colleen Lerro
- David Thomas
- George Goodno
- George MacDougall
- Jason Corum
- Jeff Joseph
- Jim Greenwood
- Karen Batra
- Kelly Cappio
- Lila Feisee
- Matt Carr
- Nathan Schock
- Paul Winters
- Paulina Ibarra
- Robbi Lycett
- Roy Zwahlen
- Sarah Sneeringer
- Sondra Behan
- Stephanie Fischer
- Stephen Marmaras
- Timothy Coetzee
- Tracy Cooley
Tags
Food indirect land use change BIO Investor Forum Food and Fuel global food crisis Greenhouse Gas Emission Climate Change ethanol Partnering Benefits of biotech crops Biofuel Technology BIO One-on-One's Plant biotechnology agriculture renewable fuel standard biotechnology Animal biotechnology greenhouse gas emissionsBusiness and Investments
Category Archives: Business and Investments
Latest From Business and Investments
A Very Big BTK January
We all heard reports that January was a great start to 2012 for the stock market, and even more so for Biotech. But how big was it, really? The Amex Biotech Index (the “BTK“) had its biggest January on record, since 1992, with a +21% pop: The companies behind the numbers? The Nasdaq Biotech Index was up 11%, the best in a decade. The January 2000 jump of 15% is still a tough month to beat Read More >
BIO CEO Company Snapshot: ImmunoGen, Inc.
In the latest Company Snapshot for the 2012 BIO CEO & Investor Conference in New York City, we’re profiling ImmunoGen, Inc. which will be presenting at the event. We spoke with ImmunoGen, Inc. CEO Daniel Junius and he outlined his organization’s priorities and challenges as well as how his company differentiates themselves from the competition. Company Snapshot What are the short-term and long-term priorities for your company? Our highest priority today is building and advancing our pipeline Read More >
Managing in a Cost-Constrained Environment
By Jill E. Sackman, D.V.M., Ph.D., Senior Consultant, and Matt Levy, J.D., Business Analyst, at Numerof & Associates, Inc. (NAI) The pharmaceutical industry has entered a critical period of transition. Business models that have proven remarkably successful over the past 20 years are now encountering major challenges. As biotech companies grapple with the leading symptoms of these challenges – pricing pressures, pipeline productivity concerns, a growing public distrust, and greater political and regulatory scrutiny – Read More >
Virginia is for (Science) Lovers
In Albemarle County, Virginia, the public school division is debuting a Health and Medical Sciences Academy this fall. Public high school students throughout the county will apply for a four-year program with a curricular concentration on skill sets that will serve state and national needs in the healthcare, pharmaceutical and research industries. In the following guest blog post, Dr. Pamela R. Moran, Superintendent of Albemarle County Public Schools, discusses this innovative program and offers insight Read More >
Biopharma Industry Enthusiastic About 2012
By Eric S. Langer, president and managing partner, BioPlan Associates, Inc. 2012 Annual Study shows budgets, optimism taking a big jump It looks like the biopharma industry is actually weathering the economic downturn quite comfortably. This year we’ve surveyed hundreds of biomanufacturers and suppliers, and the industry is expressing more raw optimism and confidence than at any time in the past 9 years we’ve been surveying this industry. More Spending What this means is that wallets Read More >
